Millions of breast cancer patients could safely avoid chemotherapy, study suggests

New study hints that millions of breast cancer patients might skip chemotherapy

Millions of breast cancer patients could – A groundbreaking international research project suggests that a significant number of breast cancer patients could safely forgo chemotherapy, thanks to a novel DNA test that helps identify who needs it most. The findings, derived from a clinical trial involving thousands of participants, challenge the traditional approach to treatment by offering a more tailored strategy for managing the disease.

Participants and Survival Rates

The study, spanning multiple countries including the UK, Norway, Sweden, Australia, New Zealand, and Thailand, included over 4,000 individuals diagnosed with breast cancer at the age of 40 or older. Researchers observed that more than two-thirds of these patients could be effectively treated with hormone therapy alone, without the need for chemotherapy. This approach not only reduces the physical toll of aggressive treatment but also preserves critical aspects of patients’ lives, such as fertility and overall well-being.

Key outcomes revealed that the survival rate for those who avoided chemotherapy was 93.7% after five years, closely matching the 94.9% survival rate of patients who received the full treatment. These figures indicate that the decision to omit chemotherapy does not compromise long-term recovery prospects, offering hope for a more patient-centered approach to care.

How the Test Works

At the heart of the study is a gene-based tool called Prosigna, which analyzes the activity of 50 specific genes linked to breast cancer progression. By evaluating these genetic markers, the test calculates a patient’s likelihood of the disease returning. Those with a low risk score, determined through this method, were excluded from chemotherapy. The results suggest that such a biological assessment could revolutionize treatment planning, moving away from one-size-fits-all protocols.

Scientists emphasize that this test measures the tumor’s intrinsic behavior rather than relying on clinical features alone. Traditional methods often depend on factors like tumor size or lymph node involvement to decide treatment, but Prosigna provides a deeper understanding of the disease’s genetic profile. This distinction is critical for identifying which patients truly benefit from chemotherapy and which can manage their condition with less invasive options.

Traditional Treatment Context

Chemotherapy remains a cornerstone of breast cancer treatment, often prescribed after surgery to eliminate any remaining cancer cells. It is especially recommended for cases where the disease has spread to nearby lymph nodes, even in early stages. However, the study raises concerns about its overuse, particularly for patients with the most common form of breast cancer. Clinicians now believe that this widespread application may not always be necessary, potentially sparing many from unnecessary side effects.

The treatment’s side effects—such as fatigue, nausea, hair loss, and immune system suppression—can be debilitating. For some patients, these challenges are compounded by the risk of early menopause or fertility issues. By using Prosigna, doctors can now make more informed decisions, reducing the burden on patients while maintaining effective care.

Impact on Patients and Healthcare

One of the trial’s participants, Karen Bonham from Cardiff, shared her relief at avoiding chemotherapy. At 64 years old, she received radiotherapy and hormone therapy instead, which she described as a “huge relief” and “like Christmas.” Her experience highlights the emotional and physical toll of chemotherapy, which can disrupt daily life and create uncertainty about the future. “Cancer diagnosis and treatment can be shocking,” Bonham said. “It certainly propels you into a world of uncertainty. Life priorities realign—you simply want to survive.”

“Cancer diagnosis and treatment can be shocking,” Bonham said. “It certainly propels you into a world of uncertainty. Life priorities realign—you simply want to survive.”

The implications of the study extend beyond individual patients. According to University College London (UCL), the findings could allow more than 5,000 NHS patients annually to bypass chemotherapy, saving healthcare resources and improving quality of life. Professor Rob Stein, the trial’s lead investigator and head of breast oncology at the UCL Cancer Institute, called the results “a significant step toward personalized treatment.”

“These results mark an important and significant step toward more personalized treatment,” Stein said. “The trial has successfully used tumour biology to guide decisions rather than relying solely on traditional clinical features.”

Stein further noted that this shift could benefit patients by alleviating the physical and emotional strain of chemotherapy. “For health systems, it represents a more efficient and evidence-based use of resources,” he added. The approach not only streamlines treatment but also reduces the risk of long-term complications, ensuring that care is both effective and tailored to individual needs.

Future Directions

While the study’s findings are promising, researchers acknowledge the need for further investigation. Currently, the test’s effectiveness is limited to patients over 40, leaving a gap in understanding its applicability to younger individuals. UCL stated that results for this demographic are expected in several years, as additional trials are underway. The study’s results will be unveiled at the American Society of Clinical Oncology’s annual meeting in Chicago, a major event in the cancer research calendar, where experts will debate their potential impact on global treatment guidelines.

The trial’s success underscores the growing importance of molecular testing in oncology. By integrating genetic data into treatment decisions, healthcare providers can move toward a model that prioritizes precision over convention. This development may lead to a paradigm shift, where chemotherapy is reserved for those who stand to gain the most from it, while others are offered alternatives that align with their specific health profiles. As the field of personalized medicine advances, such innovations could redefine how breast cancer is managed, offering a more compassionate and effective pathway for patients.